Who are Organogenesis's investors?

Organogenesis's investors include Khosla Ventures.

How much funding has Organogenesis raised?

Organogenesis has disclosed $130M raised across 1 round.

Where is Organogenesis headquartered?

Organogenesis is headquartered in Canton, US.

Organogenesis

NASDAQ: ORGO

Canton, US · Founded 1985 · 849 employees on LinkedIn · 1 known investors

Find your way into Organogenesis

416 people in our graph share verified history with the Organogenesis team — schools, employers, funds. One of them is your warm intro.

Simeon Simeonovunlockedknows Lori Freedman · together at Allaire (overlapped)

knows the team · via McDermott Will & Emery

×5knows the team · via UnitedHealth Group

×4knows the team · via Missouri State University

knows the team · via Allaire

Organogenesis is a regenerative medicine company that develops and commercializes products for the advanced wound care and surgical biologics markets, supplying clinicians and their patients. Its product portfolio includes tissue-based therapies such as Apligraf for wound care.

Biotech Healthtech Medical Devices

Founders & leadership

Gary S. Gillheeney, Sr.President & CEO

David C. FranciscoChief Financial Officer

Patrick BilboChief Operating Officer

Brian Grow Chief Commercial OfficerBrian Grow is Chief Commercial Officer at Organogenesis, a Nasdaq-listed regenerative medicine company specializing in advanced wound care and surgical biologics. With over two decades in regenerative medicine and tissue engineering, he has led commercialization of products including Apligraf and other advanced wound care biologics, bringing expertise in commercialization strategy, go-to-market execution, and pricing and reimbursement.

Lori Freedman Chief Administrative and Legal OfficerLori Freedman held chief legal officer and corporate communications roles for over 20 years, served as a business development executive for over 15 years, and previously served as number two executive officer of a publicly traded specialty pharmaceutical company for over seven years.

Antonio S. Montecalvo Vice President, Health PolicyAntonio S. Montecalvo is Vice President of Health Policy at Organogenesis, a regenerative medicine company developing wound care and surgical biologic products. He brings over two decades of experience in healthcare leadership, health policy, market access, and operations at publicly traded biotechnology companies, with expertise in national coverage determinations, reimbursement strategies, and stakeholder engagement across government and commercial payers.

Robert Cavorsi Chief Business OfficerRobert Cavorsi is Chief Business Officer of Organogenesis, a regenerative medicine company developing tissue-based therapies for wound care and surgical biologics. He brings more than 20 years of experience in biotechnology, medical devices, regenerative medicine and pharmaceuticals, with a background spanning commercial leadership, corporate strategy, business development, and M&A.

Board

Robert AdesBoard director

Alan A. AdesBoard director

Michele KorfinBoard director

Michael J. DriscollBoard director

Jon GiacominBoard director

Investors · 1

Khosla Ventureslisted by Khosla VenturesMenlo Park · $5K – $50M

How we know: Khosla Ventures's portfolio page · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$130M disclosed across 1 round · 2024

▶$130MraisedNov 2024 · 2 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Michele KorfinDirector
Michael J. DriscollDirector
Antonio MontecalvoExecutive Officer
Jon GiacominDirector
Prathyusha DuraibabuDirector
Arthur LeibowitzDirector
Robert AdesDirector
Patrick BilboExecutive Officer
Robert CavorsiExecutive Officer
Gary S. Gillheeney, Sr.Executive Officer, Director
Alan A. AdesDirector
Lori FreedmanExecutive Officer
David C. FranciscoExecutive Officer
David EraniDirector
Glenn H. NussdorfDirector
Garrett LustigDirector
Gilberto QuinteroDirector
Brian GrowExecutive Officer

Offering amount: $130M
Amount sold: $130M
Sales commissions: $5.2M
Proceeds to insiders: $23.5M
Placement agents: Truist Securities, Inc.
First sale: Nov 2024
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Organogenesis do?: Organogenesis is a regenerative medicine company that develops and commercializes products for the advanced wound care and surgical biologics markets, supplying clinicians and their patients. Its product portfolio includes tissue-based therapies such as Apligraf for wound care.
Who are Organogenesis's investors?: Organogenesis's investors include Khosla Ventures.
How much funding has Organogenesis raised?: Organogenesis has disclosed $130M raised across 1 round.
Where is Organogenesis headquartered?: Organogenesis is headquartered in Canton, US.